Posted on 03/21/2021 6:48:33 PM PDT by SeekAndFind
Americans have received more than 120 million COVID-19 vaccine doses. Another 2.4 million shots are administered each day. Within the next few months, every adult in the U.S. who wants to be vaccinated will be.
But there's a big unanswered question that affects anyone who receives a COVID-19 vaccine: How long will the vaccines provide protection against novel coronavirus infection? This isn't like the old TV game show The $64,000 Question, though. How long COVID-19 vaccines last is a multibillion-dollar question.
Billions of dollars on the line
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) were the first to win U.S. Emergency Use Authorization (EUA) for their COVID-19 vaccine, BNT162b2. In February, Pfizer estimated that the vaccine would generate sales of around $15 billion this year based on supply deals in place at that time.
However, since then the two companies have received additional orders for BNT162b2 -- 100 million more doses for the U.S. and 200 million additional doses for the European Union. These deals should boost BNT162b2 sales above $20 billion in 2021.
Moderna (NASDAQ: MRNA) won EUA for its COVID-19 vaccine, mRNA-1273, soon after Pfizer and BioNTech. The biotech expects to generate $18.4 billion in sales this year from the vaccine.
Johnson & Johnson (NYSE: JNJ) secured EUA for its single-dose COVID-19 vaccine in late February. The healthcare giant is selling the vaccine at cost during the pandemic for around $10 per dose. J&J hopes to supply at least 1 billion doses of its vaccine this year. Assuming it achieves that goal, the company will make roughly $10 billion in sales.
These three vaccines alone could together make well over $48 billion this year. And we haven't included the sales for COVID-19 vaccines from AstraZeneca (NASDAQ: AZN) and Novavax (NASDAQ: NVAX), both of which could win U.S. EUA
(Excerpt) Read more at msn.com ...
New variants could also be critical. Even if current COVID-19 vaccines provide long-lasting protection against existing coronavirus strains, the emergence of new viral variants could require more frequent booster shots.
Probably the best guess for right now is to go with Moderna CEO Stephane Bancel's prediction that COVID-19 will be like the seasonal flu. If he's right, annual vaccinations will be needed.
Long enough. You can always get a booster later, and these shots will probably be offered.
Do they provide any protection at all?
People who have been vaccinated have still gotten it.
RE: People who have been vaccinated have still gotten it.
The Vaccine makers NEVER claimed it provides 100% protection against infection.
Pfizer for instance says it is 94% effective, which means there’s a 6% change you still get infected. I think their guarantee is even if you’re infected, the symptoms will NOT be severe.
It is not Labeled as a vaccine.
Until the 12th of Never.
The answer is easy... follow the money. If they can make billions more from the sale of boosters, then guess what... you’re going to get a booster on a regular basis. This is why HCQ was trashed by the mob. No money in it.
The vaccine clinical trial results reported by Pfizer and Moderna only covered 2 months after second dose and were based on trials of carefully chosen participants. Here are some studies done by independent researchers after vaccinations.
https://www.medrxiv.org/content/10.1101/2021.03.03.21251066v1
Results: While the majority of participants in both groups produced specific IgG antibody titers against SARS-CoV-2 spike protein, titers were significantly lower in elderly participants. Although the increment of antibody levels after the second immunization was higher in elderly participants, the absolute mean titer of this group remained lower than the <60 group. After the second vaccination, 31.3 % of the elderly had no detectable neutralizing antibodies in contrast to the younger group, in which only 2.2% had no detectable neutralizing antibodies.
Conclusion: Our data suggests that lower frequencies of neutralizing antibodies after BNT162b2 vaccination in the elderly population may require earlier revaccination to ensure strong immunity and protection against infection.
_______________________________
https://www.medrxiv.org/content/10.1101/2021.03.08.21252200v1
This is the first report to date to present vaccine effectiveness (VE) estimates after the second BNT162b2 mRNA Covid-19 Vaccine. We estimated a VE of 52% and 46% in LTCF residents and HCW within seven days, which increased to 64% and 90% in the two groups respectively beyond seven days of immunization.
And the very bad news is that it may be possible to create a bioweapon that targets only people with a specific spike protein.
How long do they offer protection?
The timeline is easily identified in terms of Jack and Shit.
.....And Jack left town.
I've either gotten immunity or gotten real lucky. But among those I know who have gotten the seasonal flu shots, it doesn't seem to have made a difference.
Many of then get the flu anyway.
I'm going to pass on this one too.
It will last as long as they make a profit. Then, they will have to bring out a new vaccine for a new covid.
The short answer is that Covid-19 concentration is not gong away, as booster shots will be the next basic mandate.
Unfortunately, not even close.
https://www.advisory.com/en/daily-briefing/2021/03/02/reinfection
CDC study suggests some patients could face more severe Covid-19 with reinfection
For the report, researchers looked at two separate outbreaks that occurred three months apart at a skilled nursing facility in Kentucky. The first outbreak at the facility occurred in July 2020.
According to the researchers, among 12 of the residents who tested positive during the first outbreak and were still living at the facility in October, five—ranging in age from 67 to 99—tested positive again during the second outbreak.
Three of the five residents had asymptomatic infections during the first outbreak, but all residents experienced symptoms of Covid-19 during the second infection. One required hospitalization and later died, the researchers noted.
Further, according to the researchers, the two residents who had symptomatic cases of Covid-19 during the first outbreak experienced more severe symptoms during their second infection.
Post Reply | Private Reply | To 45 | View Replies
The mRNA "infects" the host cells and starts generating spike protein. The desired result is IgM/IgG titer against spike protein. The intended alternatives include the "toll like" response where spike protein expressed on a host cell is treated as "self" by the immune system and no defense is mounted. Viremia has been observed with that response. Another option is the IgG is created and attacks the host cells generating the spike protein. The mRNA is non-specific about what it "infects", so you have the immune system attacking the host cells on exposure to a "wild type" SARS-CoV-2 virus that triggers a response. Kills the virus and the host. Oops. This latter situation was observed in mouse studies MONTHS after the vaccine was administered. We're just jabbing now, so it may be months before this effect is observable. All the mice died.
Ping to post 17
Don’t sweat it. No one here gets out alive.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.